Multihance

(Gadobenate dimeglumine)

Phase 2Small molecule

BBracco Diagnostics, Inc

Multihance is one of 155 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

154

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Liver CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Multiple SclerosisActive, not recruiting

Coronary Artery DiseasePhase 2

Active, not recruiting

Liver CancerPreclinical

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Multiple SclerosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Multihance

BBracco Diagnostics, Inc

Phase 2

1 2

Trodelvy

Gilead

Preclinical

37 3

Zinecard

CChildren's Oncology Group

Preclinical

2 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 6

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 7

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 8

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Bisphosphonate

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Post-ApprovalRecruiting

Study completion

NCT04373564

Clinical

Trials by Indication[1]

Contrast Agent2 trials

Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries

Completed·BBracco Diagnostics, Inc·Phase 3·NCT01260636·120 enrolled

Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases

Terminated·UUniversity of Colorado, Denver·Phase 4·NCT04973007·10 enrolled

Effectiveness1 trial

Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics

Not yet recruiting·UUniversity of California, San Diego·Phase 3·NCT06406517·160 enrolled

Multiple Sclerosis1 trial

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

Terminated·UUniversity of Southern California·N/A·NCT02967380·14 enrolled

Breast Cancer1 trial

Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT03703492·12 enrolled

Treatment1 trial

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

Completed·MM.D. Anderson Cancer Center·N/A·NCT04132843·6 enrolled

8 more indications

Safety and Efficacy1 trial

Safety and Efficacy of MultiHance in Pediatric Patients

Terminated·BBracco Diagnostics, Inc·Phase 3·NCT00323310·92 enrolled

Prostate Cancer1 trial

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Withdrawn·NNorthwestern University·Phase 2·NCT04910425

Coronary Artery Disease1 trial

Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

Completed·UUniversity of Utah·Phase 2·NCT01710254·30 enrolled

Magnetic Resonance Imaging (MRI)1 trial

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Completed·GGuerbet·Phase 2·NCT02633501·312 enrolled

CAR1 trial

QSM and Regional DCE MRI Permeability Using GOCART Technique

Withdrawn·UUniversity of Southern California··NCT03091803

Pediatric Patients1 trial

Retrospective Study of MRI in Pediatric Patients

Completed·BBracco Diagnostics, Inc··NCT02291822·90 enrolled

Liver Cancer1 trial

Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·N/A·NCT00539253·45 enrolled

Unspecified1 trial

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Recruiting·GGuerbet·Phase 4·NCT04373564·2,076 enrolled

Regulatory

FDA Approval Timeline[4]

Nov 23, 2004

MULTIHANCE

NDA NDA021357

Nov 23, 2004

MULTIHANCE MULTIPACK

NDA NDA021358

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Gadobenate dimeglumine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gadobenate dimeglumine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gadobenate dimeglumine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021357). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bracco Diagnostics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBracco Diagnostics, Inc

Multihance

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Contrast Agent2 trials

Effectiveness1 trial

Multiple Sclerosis1 trial

Breast Cancer1 trial

Treatment1 trial

Safety and Efficacy1 trial

Prostate Cancer1 trial

Coronary Artery Disease1 trial

Magnetic Resonance Imaging (MRI)1 trial

CAR1 trial

Pediatric Patients1 trial

Liver Cancer1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News